Fage
An daɗe da sanin hanyoyin kwantar da hankali na tushen incretin don inganta duka biyunsarrafa glucose na jinikumarage nauyin jiki. Magungunan incretin na al'ada da farko suna kaiwa gaGLP-1 mai karɓa, yayin daTirzepatideyana wakiltar sabon ƙarni na "twincretin” wakilai - aiki akanduka GIP (glucose-dogara insulinotropic polypeptide)kumaGLP-1masu karɓa.
An nuna wannan aikin dual don haɓaka fa'idodin rayuwa da haɓaka asarar nauyi idan aka kwatanta da GLP-1 agonists kaɗai.
Zane-zanen Nazarin SURMOUNT-1
SURMOUNT-1ya kasance abazuwar, makafi biyu, gwaji na asibiti lokaci 3da aka gudanar a fadin shafuka 119 a kasashe tara.
Mahalarta taron sun haɗa da manya waɗanda su ne:
- Kiba(BMI ≥ 30), ko
- Kiba mai yawa(BMI ≥ 27) tare da aƙalla nau'i mai alaƙa da nauyin nauyi (misali, hauhawar jini, dyslipidemia, apnea barci, ko cututtukan zuciya).
Mutanen da ke da ciwon sukari, amfani da magungunan rage kiba na baya-bayan nan, ko aikin tiyata na bariatric kafin a cire su.
An keɓe mahalarta ba da gangan ba don karɓar alluran sati-sati ɗaya na:
- Tirzepatide 5 MG, 10 mg, 15 mg, ko
- Placebo
Duk mahalarta kuma sun sami jagorar rayuwa:
- A caloric rashi na 500 kcal / rana
- AkallaMinti 150 na motsa jiki a kowane mako
Magani ya dadesati 72, harda aMatakin haɓaka kashi-mako 20biye da lokacin kulawa na mako 52.
Bayanin Sakamakon
Jimlar2,359 mahalartaan sanya su.
Matsakaicin shekarun ya kasance44.9 shekaru, 67.5% mata ne, tare da ma'ananauyin jiki na 104.8 kgkumaBMI na 38.0.
Ma'anar Rage Nauyin Jiki a Mako na 72
| Rukunin kashi | % Canjin Nauyi | Ma'anar Canjin Nauyi (kg) | Ƙarin Asara vs Placebo |
|---|---|---|---|
| 5 mg | -15.0% | - 16.1 kg | -13.5% |
| 10 mg | -19.5% | - 22.2 kg | -18.9% |
| 15 mg | -20.9% | - 23.6 kg | -20.1% |
| Placebo | -3.1% | - 2.4 kg | - |
Tirzepatide ya sami 15-21% yana nufin rage nauyin jiki, yana nuna bayyananniyar tasirin dogaro da kashi.
Kashi na Mahalarta Suna Samun Rage Nauyin Maƙasudi
| Rage nauyi (%) | 5 mg | 10 mg | 15 mg | Placebo |
|---|---|---|---|---|
| ≥5% | 85.1% | 88.9% | 90.9% | 34.5% |
| ≥10% | 68.5% | 78.1% | 83.5% | 18.8% |
| ≥15% | 48.0% | 66.6% | 70.6% | 8.8% |
| ≥20% | 30.0% | 50.1% | 56.7% | 3.1% |
| ≥25% | 15.3% | 32.3% | 36.2% | 1.5% |
Fiye da rabina mahalarta karba≥10 MGTirzepatide ya samu≥20% asarar nauyi, gabatowa tasirin da aka gani tare da tiyata na bariatric.
Amfanin Metabolic da Zuciya
Idan aka kwatanta da placebo, Tirzepatide ya inganta sosai:
- Da'irar kugu
- Systolic hawan jini
- Bayanan martaba
- Matakan insulin masu azumi
Daga cikin mahalarta tare daciwon sukari, 95.3% sun koma matakan glucose na yau da kullun, daura da61.9%a cikin rukunin placebo - yana nuna Tirzepatide ba wai kawai yana taimakawa rage nauyi ba amma yana haɓaka metabolism na glucose.
Tsaro da Haƙuri
Mafi yawan illolin da aka fi sani sunena ciki, ciki har datashin zuciya, gudawa, da maƙarƙashiya, galibi mai laushi kuma mai wucewa.
Adadin dakatarwa saboda munanan al'amura ya kai kusan4-7%.
An samu wasu ‘yan mace-mace a yayin gwajin, wadanda ke da alaka da suCUTAR COVID 19, kuma ba su da alaƙa kai tsaye da maganin binciken.
Ba a sami bambance-bambance masu mahimmanci a cikin matsalolin da ke da alaƙa da gallbladder ba.
Tattaunawa
Gyaran salon rayuwa kaɗai (abinci da motsa jiki) yawanci yana samarwa kawai~ 3% matsakaicin asarar nauyi, kamar yadda aka gani a cikin rukunin placebo.
Sabanin haka, Tirzepatide yana kunna15-21% jimlar rage nauyin jiki, wakiltar a5-7 sau mafi girma sakamako.
Idan aka kwatanta da:
- Magungunan asarar nauyi na baka:yawanci cimma 5-10% hasara
- Tiyatar Bariatric:ya samu> 20% hasara
Tirzepatide ya haɗu da rata tsakanin magungunan magunguna da ayyukan tiyata - bayarwamai ƙarfi, rage nauyi mara nauyi.
Mahimmanci, ba a lura da damuwa game da tabarbarewar metabolism na glucose ba. Akasin haka, Tirzepatide ya inganta haɓakar insulin kuma yana juyar da prediabetes a yawancin mahalarta.
Koyaya, wannan gwaji ya kwatanta Tirzepatide tare da placebo - ba kai tsaye tare daSemaglutide.
Ana buƙatar kwatanta kai-da-kai don sanin wane wakili ne ke haifar da asarar nauyi.
Kammalawa
Ga manya masu fama da kiba ko kiba da cututtukan da ke da alaƙa, ƙaraTirzepatide sau ɗaya a makozuwa tsarin tsarin rayuwa (abinci + motsa jiki) na iya haifar da:
- 15-21% matsakaiciyar rage nauyin jiki
- Mahimman cigaban rayuwa
- Babban haƙuri da aminci
Tirzepatide don haka yana wakiltar ingantaccen magani mai inganci kuma ingantaccen asibiti don ɗorewa, kulawar nauyi na likitanci.
Lokacin aikawa: Oktoba-16-2025